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1. Introduction  
Bipolar disorder (previously also labeled manic-depressive illness) is typically referred to as 
an episodic, yet lifelong and clinically severe affective (or mood) disorder, affecting 
approximately 3.5% of the population (Marmol, 2008; Simon, 2003; Wittchen et al., 2003; 
Woods, 2000). The term bipolar disorder, however, encompasses several phenotypes of 
mood disorders, i.e. mania, hypomania or cyclothymia that may present with a puzzling 
variety of other symptoms and disorders. According to the Fourth Edition of the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-IV) (American Psychiatric Association, 
2004), the diagnostic classificatory system used in most epidemiological studies, bipolar 
disorder is defined by a set of specific symptom criteria. Bipolar type I requires the presence 
or the history of at least one manic or mixed episode. Although, typically, patients with a 
manic episode also experience major depressive episodes, bipolar disorder can be diagnosed 
even if only one manic episode and no past major depressive episodes are present. Bipolar 
disorder type II differs from type I only by presence of hypomanic but no manic episodes. 
Hypomanic episodes differ from mania by a shorter duration (at least 4 days instead of 1 
week), and less severe impairment (not severe enough to cause marked impairment in social 
or occupational functioning, psychiatric hospitalization, or psychotic features). The DSM-IV 
also includes “cyclothymia” as a bipolar spectrum disorder with hypomanic as well as 
depressive episodes that do not meet criteria for major depression (American Psychiatric 
Association, 2004). 
Bipolar disorder is a chronic disease that is associated with a potentially devastating impact 
on patients’ wellbeing and social, occupational, and general functioning (Revicki et al., 
2005). The disorder ranks as the sixth leading cause of disability in the world, with an 
economic burden that in the US alone that was estimated more than a decade ago at $7 
billion in direct medical costs and $38 billion (1991 values) in indirect costs (Wyatt et al., 
1991). 
A number of reviews and studies have shown that people with severe mental illness, 
including bipolar disorder, have an excess mortality, being two or three times as high as that 
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in the general population. This mortality gap, which translates to a 13-30 year shortened life 
expectancy in severe mental illness patients, has widened in recent decades, even in 
countries where the quality of the health care system is generally acknowledged to be good. 
About 60% of this excess mortality is due to physical illness especially cardiovascular 
disease. Additionally, several studies have found that after suicide and accidents, 
cardiovascular and all vascular diseases are the main leading causes of death in these 
patients (De Hert et al., 2011; Garcia-Portilla et al., 2009). 
Patients with bipolar disorder, especially type I, are known to suffer a considerable number 
of associated pathologies that may manifest at earlier ages and with higher frequency than 
in the general population. The most recent studies have explored cardiovascular risk and the 
association with metabolic and endocrine disorders fundamentally, obesity and metabolic 
syndrome which are clearly associated with the development of cardiovascular disease 
(Angst et al., 2002; Sicras et al., 2008). 
Cardiovascular disease, i.e. coronary heart disease, stroke, and peripheral vascular disease, 
are potentially preventable diseases. Thanks to epidemiological, experimental and clinical 
studies, the primary determinants of cardiovascular disease have been identified, as well as 
the efficacy of specific interventions. The prevalence of cardiovascular disease is increasing 
in less urbanized, developed populations across the world, as their lifestyles change to a so 
called “western style”, with increasing consumption of dietary saturated fat, cholesterol and 
salt, cigarette smoking, decreased physical activity and the rise in cardiovascular risk factors 
including obesity and diabetes. Other known factors that contribute to cardiovascular 
disease risk are stress and high alcohol intake. Among all these factors, 
hypercholesterolemia is the leading cause of death from cardiovascular disease. As a result, 
public health agencies have attempted to reduce the prevalence of hypercholesterolemia 
through screening and by increasing public awareness and strategies for reducing it 
(Muntoni et al., 2009). 
The exact mechanisms increasing the incidence of cardiovascular risk in bipolar patients 
remain to be clarified, but they possibly include industrialisation, stress, lack of exercise, 
dietary lipids (that is, omega-3 fatty acid deficiency) and increasing incidence of smoking 
and alcohol consumption and other factors (Ezzaher et al., 2010).  
This study aims to investigate the principal factors predisposing to the cardiovascular risk in 
Tunisian bipolar I patients (cigarette smoking, hypertension, diabetes, obesity, lipid profile, 
hyperhomocysteinemia and metabolic syndrome) and to determine the association between 
these factors and the clinical and therapeutic characteristics of bipolar I disorder.  
2. Patients and methods 
2.1 Subjects 
This study was approved by the local ethical committee and all subjects were of Tunisian 
origin. Our samples included 130 patients with bipolar I disorder (37.9 ± 12.1 years) from the 
psychiatry department of the University Hospital of Monastir, Tunisia, 45 women (37.5 ± 
13.4 years) and 85 men (38.1 ± 11.4 years). Consensus on the diagnosis, according to the 
Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria 
(American Psychiatric Association, 2004), was made by psychiatrists. The exclusion criteria 
were age < 18 years, other psychiatric illnesses, epilepsy or mental retardation. The control 
group consisted of 175 volunteer subjects without psychiatric pathology. The mean age was 
40.1 ± 14.0 years, and there were 73 women (42.0 ± 14.4 years) and 102 men (38.8 ± 13.6 
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years). All subjects were questioned about their age, gender, previous treatments and 
cigarette and alcohol consumption habits.  
The clinical and socio-demographic characteristics are shown in table 1. Differences between 
patients and controls for body mass index (BMI) (p < 0.001) and smoking status (p =0.025) 
were noted. Therefore, these variables were considered as potential confounder factors for 
this analysis.  
 
 
Patients 
(n = 130) 
Controls 
(n = 175) 
p 
Gender: Men/Women (ratio) 85/45 (1.89) 102/73 (1.39) 0.143 
Age (years) (mean ± SD) 37.9 ± 12.1 40.1 ± 14.0 0.840 
BMI (kg/m²) (M ± ET) 27.1 ± 4.6 25.3 ± 4.1 < 0.001 
 Nombre % Nombre % p 
BMI (kg/m²) 
< 25 47 36.2 89 50.9 
< 0.001 [25-30[ 40 30.7 72 41.1 
≥ 30 43 33.1 14 8 
Cigarette smoking
Yes 68 52.3 69 39.4 
0.025 
No 62 47.7 106 60.6 
Alcoholic beverages
Yes  17 13.1 12 6.9 
0.067 
No 113 86,9 163 93.1 
Illness episode 
Depressive 21 16.2 - - - 
Euthymic  73 56.1 - - - 
Manic 36 27.7 - - - 
Treatment 
Valproic acid 64 49.3 - - - 
Lithium 12 9.2 - - - 
Carbamazepine 10 7.7 - - - 
Valproic acid and lithium 6 4.6 - - - 
Antipsychotics 38 29.2 - - - 
Antipsychotics: Haloperidol, Risperidone, Chlorpromazine, Olanzapine; BMI: body mass index 
Table 1. Sociodemographic and therapeutic characteristics of studied population. 
2.2 Samples 
After a 12 h overnight fasting, venous blood for each patient was drawn in tubes containing 
lithium heparinate and immediately centrifuged. The plasma samples were stored at -20°C 
until the biochemical analysis. 
2.3 Biochemical analysis 
The methods of dosage and the normal values of the different biological parameters are 
shown in table 2. 
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Parameters Assay Automates Normal values 
Cholesterol 
Enzymatic  
Konelab 30 
equipment 
(Thermo 
Electron 
Corporation, 
Ruukintie, 
Finland) 
< 5.17 mmol/L 
Triglycerides < 1.7 mmol/L 
c-HDL 
Men: ≥ 1.1 mmol/L 
Women: ≥ 0.9 mmol/L 
c-LDL < 3.4 mmol/L 
ApoA1 
 
Immunoturbidimetry 
1.2- 1.6 g/L 
ApoB 0.7-1.3 g/L 
Lp(a) < 200 mg/L 
Uric acid Enzymatic 
Men: 210-420 µmol/L 
Women: 150-360 
µmol/L 
Homocysteine 
Fluorescence polarization 
(FPIA) 
AxSYM® 
(Abbott 
Laboratories, 
Abbott Park, IL 
60064, 
Barcelaneta, 
Puerto Rico) 
< 15 µmol/L 
Vitamin B12 
Electrochemiluminescence 
Elecsys 2010TM 
(Roche 
Diagnostics, 
Indianapolis, IN, 
USA) 
≥ 187ng/L 
Folate ≥ 3.7 µg/L 
Insulin < 17µU/mL 
Table 2. Methods of dosage of the studied parameters. 
2.4 Clinical evaluation 
Body mass index (BMI) was calculated as weight (kg) divided by height (m²). Obesity was 
defined when BMI ≥ 30 kg/m² and overweight when BMI ≥ 25 kg/m² (World Health 
Organization, 1997). 
2.5 Criteria for metabolic syndrome 
Metabolic syndrome (MS) was defined according to the National Cholesterol Education 
Program (NCEP) Adult Treatment Panel (ATP) III modified criteria and required fulfillment 
of at least three of the following five components: body mass index (BMI) ≥ 28.5 kg⁄m2, 
triglycerides ≥ 1.7 mmol/L, high-density lipoprotein cholesterol (c-HDL) < 1.1 mmol/L (in 
men) and < 0.9 mmol/L (in women), blood pressure ≥ 130 ⁄85 mmHg and fasting glucose (≥ 
6.1 mmol/L) (National Cholesterol Education Program, 2002). 
2.6 HOMA-IR determination 
Insulin resistance (IR) was estimated using the Homeostasis Model of Assessment equation: 
HOMA-IR = [fasting insulin (mU/L) × fasting glucose (mmol/L)]/22.5. IR was defined as 
the upper quartile of HOMA-IR. Values above 2.5 were taken as abnormal and reflect 
insulin resistance (Ozdemir et al., 2007). Bipolar patients with diabetes (n = 21) were 
excluded in the HOMA-IR analysis. 
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2.7 Statistical analysis  
Statistical analyses were performed using SPSS 17.0 (SPSS, Chicago, IL, USA). Quantitative 
variables were presented as mean ± SD and comparisons were performed using the 
Student's t test. Qualitative variable comparisons were performed using the Chi-squared test 
(χ2) and Fisher’s exact test (when n < 5). Comparisons between patients and controls in 
biological parameters were performed using analysis of variance (ANOVA) after adjustment 
for potential confounder factors. Odd ratios (ORs) and their 95% confidence interval (CI) 
were calculated and adjusted for potential confounder factors by binary logistic regression. 
The statistical significance level was set at p < 0.05. All variables with a p value < 0.25 
between the two studied groups (patients and controls) were considered as potential 
confounder factors for this analysis. 
3. Results 
Table 3 shows the comparisons of biological variables between bipolar I patients and controls. 
 
Biological variables 
Patients 
(n = 130) 
Controls 
(n = 175) 
p p* 
Triglycerides (mmol/L) 1.95 ± 1.55 1.23 ± 0.81 < 0.001 < 0.001 
Cholesterol (mmol/L) 4.42 ± 0.99 4.37 ± 1.26 0.707 0.856 
c-LDL (mmol/L) 2.14 ± 1.10 2.37 ± 1.38 0.118 0.047 
c-HDL (mmol/L) 
Men (85/102) 1.04 ± 0.37 0.98 ± 0.29 0.192 0.017 
Women (45/73) 1.17 ± 0.36 1.21 ± 0.48 0.542 0.702 
ApoA1 (g/L) 1.20 ± 0.23 1.40 ± 0.67 < 0.001 0.028 
ApoB (g/L) 0.82 ± 0.28 0.83 ± 0.24 0.784 0.777 
ApoB/Apo A1 0.71 ± 0.26 0.65 ± 0.25 0.086 0.314 
Lp(a) (mg/L) 243 ± 223 87 ± 129 < 0.001 < 0.001 
Homocysteine (µmol/L) 15.8 ± 8.9 11.5 ± 5.0 < 0.001 < 0.001 
Vitamin B12 (ng/L) 356 ± 198 360 ± 190 0.837 0.819 
Folate (µg/L) 3.3 ± 0.9 5.1 ± 2.8 < 0.001 <0.001 
Uric acid (µmol/L) 
Men (85/102) 311 ± 99 250 ± 107 0.001 0.005 
Women (45/73) 246 ± 97 197 ± 73 0.012 0.408 
* Lipid profile parameters, folatemia, vitamin B12 and uric acid were adjusted for gender, BMI, cigarette 
smoking, alcoholic beverages, diabetes and hypertension 
*Hcys was adjusted for gender, BMI, cigarette smoking, alcoholic beverages, diabetes, hypertension, 
folatemia and vitamin B12 
Table 3. Comparisons of biological variables between bipolar I patients and controls. 
Compared with controls, patients had significantly higher triglycerides (1.95 ± 1.55 Vs 1.23 ± 
0.81 mmol/L; p < 0.001), Lp(a) (243 ± 223 Vs 87 ± 129 mg/L; p < 0.001), homocysteine levels 
(15.8 ± 8.9 Vs 11.5 ± 5.0 µmol/L; p < 0.001) and uric acid (311 ± 99 Vs 250 ± 107 µmol/L;  
p = 0.001 in men; 246 ± 97 Vs 197 ± 73 µmol/L; p = 0.012 in women), and significantly lower 
ApoA1 (1.20 ± 0.23 Vs 1.40 ± 0.67 g/L; p < 0.001) and folate (3.3 ± 0.9 Vs 5.1 ± 2.8 µg/L;  
p < 0.001) levels. After adjustment for potential confounder factors, these differences 
remained significant for all of these parameters except for uric acid which is remained 
significantly higher only for men (table 3). 
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Table 4 reports the association between bipolar I disorder and cigarette smoking, alcoholic 
beverages, obesity, diabetes, hypertension, lipid profile parameters, hyperhomocysteinemia, 
hypofolatemia, hypovitamin B12 and, hyperuricemia. 
 
Parameters 
Patients
(n = 130)
Controls
(n = 175)
OR IC 95% p OR* p* 
Cigarette 
smoking 52.3% 39.4% 1.68 1.06-2.66 0.025 - - 
Alcoholic 
beverages 13.1% 6.9% 2.04 0.94-4.44 0.067 - - 
Obesity (BMI ≥ 
30 kg/m²) 33.1% 8% 5.68 
2.94-
10.96 
< 0.001 8.69 < 0.001 
Diabetes ≥ 6.1 
mmol/L 
16.1% 9.7% 1.79 0.90-3.55 0.092 1.60 0.325 
Hypertension  
(≥ 130/85 mm 
Hg) 
5.4% 16% 0.34 0.15-0.78 0.008 0.43 0.136 
Hypercholesterol
emia (≥ 5.17 
mmol/L) 
26.2% 26.9% 0.96 0.57-1.61 0.891 0.99 0.987 
Hypertriglycerid
emia (≥ 1.7 
mmol/L)  
53.1% 17.7% 4.10 2.44-6.90 < 0.001 3.71 < 0.001 
HyperLDL  
(≥ 3.4 mmol/L) 13.1% 26.9% 0.39 0.22-0.73 0.002 0.48 < 0.001 
¥HypoHDL 59.2% 58.3% 1.00 0.63-1.59 0.975 0.78 0.359 
HyperLp(a) 
(≥ 200 mg/L)  47.7% 14.8% 5.25 3.04-9.07 < 0.001 4.48 < 0.001 
Hyperhomocyste
inemia  
(≥15 µmol/L) 
39.2% 18% 2.80 1.66-4.72 < 0.001 1.95 0.038 
Hypovitamin 
B12  
(< 187 ng/L) 
21.2% 14.9% 0.69 0.34-1.38 0.296 0.62 0.215 
Hypofolatemia 
(< 3.7 µg/L) 
66.2% 36.2% 3.44 2.13-5.54 < 0.001 3.69 < 0.001 
£Hyperuricemia 10.8% 4.4% 2.05 0.71-5.91 0.176 1.58 0.439 
* Lipid profile parameters, folatemia, vitamin B12 and uric acid were adjusted for gender, BMI, cigarette 
cigarette smoking, alcoholic beverages, diabetes and hypertension; * Hcys was adjusted for gender, 
BMI, cigarette smoking, alcoholic beverages, diabetes, hypertension, folatemia and vitamin B12; 
*Diabetes was adjusted for gender, BMI, cigarette smoking, alcoholic beverages, hypertension and 
dyslipidemia; *Obesity was adjusted for gender, cigarette smoking, alcoholic beverages, hypertension, 
diabetes and dyslipidemia; *Hypertension was adjusted for gender, cigarette smoking, alcoholic 
beverages, diabetes and dyslipidemia; \ c-HDL <1.1 mmol/L (in men) and < 0 .9 (in women); £ uric 
acid: 210-420 µmol/L (in men) and 150-360 µmol/L ( in women)  
Table 4. Association between bipolar I disorder and cigarette smoking, alcoholic beverages, 
obesity, diabetes, hypertension, lipid profile parameters, hyperhomocysteinemia, 
hypofolatemia, hypovitamin B12, and hyperuricemia. 
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We showed significant association between bipolar I disorder and some cardiovascular risk 
factors: obesity (33.1% Vs 8%, OR = 5.68, IC 95% = 2.94-10.96; p < 0.001), hyperLp(a) (47.7% 
Vs 14.8%, OR = 5.25, IC 95% = 3.04-9.07; p < 0.001), hypertriglyceridemia (53.1% Vs 17.7%, 
OR = 4.10, IC 95% = 2.44-6.90; p < 0.001), hypofolatemia (66.2% Vs 36.2%, OR = 3.44, IC 95% 
= 2.13-5.54; p < 0.001), hyperhomocysteinemia (39.2% Vs 18%, OR = 2.80, IC 95% = 1.66-4.72; 
p < 0.001) and cigarette smoking (52.3% Vs 39.4%, OR = 1.68, IC 95% = 1.06-2.66;  
p = 0,025). After adjustment for potential confounder factors, these associations remained 
significant (table 4). 
Alcoholic beverage, diabetes and hyperuricemia were not significantly associated with this 
illness but we showed that they were more frequents in patients than controls (13.1% Vs 
6.9%, p = 0.067; 16.1% Vs 9.7%, p = 0.325; 10.8% Vs 4.4%, p = 0.439; respectively). 
Additionally, the risk of diabetes and hyperuricemia were respectively multiplied by 1.5 in 
patients (16.1% Vs 9.7%, OR = 1.60, IC 95% = 0.62-4.12; p = 0.325; 10.8% Vs 4.4%, OR = 1.58, 
IC 95% = 0.49-5.08; p = 0.439) and the risk of alcoholic beverage by two (13.1% Vs 6.9%, OR = 
2.04, IC 95% = 0.94-4.44; p = 0.067) (table 4).  
On the contrary, this disease was not associated with hypertension (5.4% Vs 16%, OR = 0.43, 
IC 95% = 0.14-1.29; p = 0.136) nor with hyperLDL (13.1% Vs 26.9%, OR = 0.48, IC 95% = 2.53-
7.95; p < 0.001) (table 4). 
Fig.1. illustrates the receiver Operating Characteristic (ROC) of three index of atherogenicity 
as predictive factors of cardiovascular risk. 
 
 
TG: triglycerides; CT: cholesterol 
Fig. 1. Receiver Operating Characteristic (ROC) of three index of atherogenicity as predictive 
factors of cardiovascular risk. 
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The specificity and sensibility of three index of atherogenicity as predictive factors of 
cardiovascular risk are shown in table 5. 
 
Parameters 
AUC  
(95% CI) 
Cut off Specificity Sensibility p 
TG/HDL 
0.65  
[0.59-0.71] 
1.12 0.63 0.62 < 10-3 
CT/HDL 
0.52  
[0.44-0.57] 
3.93 0.53 0.57 0.661 
ApoB/ApoA1 
0.56  
[0.49-0.62] 
0.66 0.54 0.55 0.070 
TG: triglycerides; CT: cholesterol; AUC; Area under the curve 
Table 5. Specificity and sensibility of three index of atherogenicity as predictive factors of 
cardiovascular risk 
Fig. 2. Illustrates the Receiver Operating Characteristic (ROC) of Lp(a) and homocysteine as 
predictive factors of cardiovascular risk. 
 
 
Fig. 2. Receiver Operating Characteristic (ROC) of Lp(a) and homocysteine as predictive 
factors of cardiovascular risk. 
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Table 6 reports the specificity and sensibility of Lp(a) and homocysteine as predictive factors 
of cardiovascular risk. 
 
Parameters AUC (95% CI) Cut off Specificity Sensibility p 
Lp(a) (mg/L) 0.80 [0.75-0.85] 168 0.75 0.74 < 10-3 
Homocysteine (µmol/L) 0.52 [0.44-0.57] 13.4 0.60 0.62 < 10-3 
AUC; Area under the curve 
Table 6. Specificity and sensibility of Lp(a) and homocysteine as predictive factors of 
cardiovascular risk. 
TG/HDL ratio and Lp(a) were found as the best predictive factors of cardiovascular risk in 
terms of sensibility (0.62, 0.74; respectively) and specificity (0.63, 0.75; respectively) at 
threshold of 1.12 and 168 mg/L, respectively (tables 5, 6; fig 1, 2). 
The prevalence of metabolic syndrome (modified NCEP-ATP III) and its profile in bipolar I 
patients are shown in table 7. 
 
 N % 
Total of the association of 5 criteria 2 5.9 
     Diabetes, Obesity, Hypertriglyceridemia, Low c-HDL 1  
     Diabetes, Obesity, Low c-HDL, High blood pressure 1  
     Diabetes, Hypertriglyceridemia, Low c-HDL, High blood pressure 1  
Total of the association of 4 criteria 3 8.8 
     Obesity, Hypertriglyceridemia, Low c-HDL 15  
     Diabetes, Low c-HDL, Hypertriglyceridemia 6  
     Obesity, Hypertriglyceridemia, Diabetes 4  
     Obesity, Hypertriglyceridemia, High blood pressure 2  
     Diabetes , High blood pressure, Obesity 1  
     Hypertriglyceridemia, Low c-HDL, High blood pressure 1  
Total of the association of 3 criteria 29 85.3 
At least three or more criteria 34 100 
Table 7. Prevalence of metabolic syndrome (modified NCEP-ATP III) and its profile in 
bipolar I patients. 
The prevalence of metabolic syndrome in bipolar I patients was 26.1% (N = 34). The highest 
prevalence of this syndrome was obtained by the association between obesity, low c-HDL 
and hypertrilyceridemia (44.1 %) (Table 7). 
Table 8 reports the Prevalence of the components of metabolic syndrome in the total sample 
of bipolar I patients. 
 
Criteria N (%) 
c-HDL <  1.1 mmol/L (men) and < 0 .9 (women) 77(59.2) 
TG  ≥ 1.7 mmol/L 69(53.1) 
BMI  ≥  28.5 kg/m² 44 (33.8) 
Fasting blood glucose ≥ 6.1 mmol/L 21 (16.1) 
Blood pressure  ≥ 130/85 mm Hg 7(5.4) 
Table 8. Prevalence of the components of metabolic syndrome in the total sample (N=130). 
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The prevalence of individual diagnostic components, in the total sample, was as follows: 
59.2% for low c-HDL, 53.1% for hypertriglyceridemia, 33.8% for obesity (BMI ≥ 28.5 kg/m²), 
16.1% for high fasting glucose and 5.4% for hypertension (Table 8). 
Table 9 reports the characteristics of patients with or without metabolic syndrome. 
 
 
With MS 
[N= 34 (26.1%)] 
Without MS 
[N= 96 (73.9%)] 
p values 
Variables N (% ) N (%)  
Gender 
Men 21 (24.7) 64 (75.3) 
0.60 
Women 13 (28.9) 32 (71.1) 
Illness episode 
Depressive 4 (19) 17 (81) 
0.651a 
 
Euthymic 19 (26) 54 (74) 
Manic 11 (30.5) 25 (69.5) 
Treatment    
Antipsychotics 10 (26.3) 28 (73.7) 
 
0.9574a 
 
Mood stabilizers 24 (26.1) 68 (74.9) 
Lithium 4 (33.3) 8 (66.7) 
Valproic acid 17 (26.6) 47 (73.4) 
Carbamazepine 2 (20) 8 (80) 
Lithium and valproic acid 1 (16.7) 5 (83.3) 
 Mean ± SD Mean ± SD p 
Age (years) 40.4 ± 8.8 37.0 ± 12.7 0.11 
HOMA-IR 6.0 ± 4.3* 2.4 ± 1.7** < 0.001 
Uric acid (µmol/L) 335 ±117 272 ± 92 < 0.001 
* n = 23 (11 diabetic patients were excluded);  
** n = 86 (10 diabetic patients were excluded 
aStatistical analysis was detected using Fisher’s exact test 
Table 9. Characteristics of patients with or without metabolic syndrome.  
We found that gender was not associated with metabolic syndrome, 24.7% in men and 
28.9% in women. As to age, we found that patients with metabolic syndrome were older 
than metabolic syndrome free patients (40.4 ± 8.8 years Vs 37.0 ± 12.7 years), but this 
difference was not significant (table 9).  
Our present data showed that there is no difference in metabolic syndrome prevalence 
between patients receiving antipsychotic and mood stabilizers treatment. However, we 
noted that patients treated with lithium had the highest prevalence of metabolic syndrome 
(table 9). 
Our study failed to show any significant association between metabolic syndrome and illness 
episode, whereas, manic patients had the highest prevalence of this disorder (30.5%) (table 9). 
Patients with metabolic syndrome had significantly higher levels of uric acid (p < 0.001) 
than metabolic syndrome free patients (table 9).  
Concerning HOMA-IR analysis, after diabetic patients exclusion (n = 21), we noted that 
patients with metabolic syndrome had significantly higher levels of HOMA-IR (p < 0.001) 
than metabolic syndrome free patients (table 9). 
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The variations of lipid profile parameters according to the illness episode and therapeutic 
characteristics of bipolar I patients are shown in table 10.  
 
 
Triglycerides
(mmol/L) 
Cholesterol
(mmol/L) 
c-HDL (mmol/L)
c-LDL 
(mmol/L)
Lp (a) 
(mg/L) 
 
ApoB/Apo
A1 
 Men Women
Patients 
(n = 130) 
1.95 ± 1.55 4.42 ± 0.99 
1.04 ± 
0.37 
1.17 ± 
0.36 
2.14 ± 
1.10 
243 ± 
223 
0.71 ± 0.23 
Illness episode 
Depressive 
(n = 21) 
1.95 ± 1.32 4.49 ± 0.96 
1.12 ± 
0.28 
0.99 ± 
0.36 
2.14 ± 
1.09 
158 ± 91 0.82 ± 0.41 
Euthymic 
(n = 73) 
1.94 ± 1,80 4.53± 0.96 
1.05 ± 
0.41 
1.26 ± 
0.33 
2.18 ± 
1.04 
268 ± 
242 
0.68 ± 0.19 
Manic 
(n = 36) 
1.97 ± 1.25 4.14 ± 1.0 
0.98 ± 
0.32 
1.10 ± 
0.11 
2.08 ± 
1.25 
240 ± 
228 
0.70 ± 0.26 
Treatment 
Valproic 
acid 
(n = 64) 
1.78 ± 1.20 4.25 ±1.00 
1.05 ± 
0.40 
1.13 ± 
0.24 
2.11 ± 
1.12 
240 ± 
232 
0.70 ± 0.24 
Lithium 
(n = 12) 
1.43 ± 0.95 4.40 ± 0.85 
1.10 ± 
0.36 
0.86 ± 
0.49 
2.17 ± 
0.82 
170 ± 93 0.78 ± 0.29 
Carbamaze
pine 
(n = 10) 
2.24 ± 3.25 4.60 ± 1.10 
0.97 ± 
0.33 
1.44 ± 
0.40 
1.75 ± 
0.74 
293 ± 
221 
0.66 ± 0.22 
AVP and Li 
(n =6) 
2.33 ± 1.07 3.93 ± 0.40 
1.10 ± 
0.28 
0.79 
2.10 ± 
1.22 
153 ± 69 0.76 ± 0.23 
Anti-
psychotics 
(n = 38) 
2.26 ± 1.64 4.74 ± 1.00 
1.03 ± 
0.36 
1.26 ± 
0.40 
2.30 ± 
1.23 
271 ± 
248 
0.71 ± 0.30 
AVP: valproic acid; Li: lithium 
Table 10. Variations of lipid profile parameters according to the illness episode and 
therapeutic characteristics of bipolar I patients. 
Our study failed to show any significant association between lipid profile parameters, 
illness episode and treatment, while euthymic patients were found to have the highest levels 
of Lp(a) and depressive patients had the highest levels of ApoB/ApoA1 ratio (table 10). 
Additionally, we showed that women taking lithium had the lowest c-HDL values and 
patients taking carbamazepine had the highest values of Lp(a) (table 10).  
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Table 11 reports the variations of uric acid, homocysteine, folate and vitamin B12 
concentrations according to the illness episode and therapeutic characteristics of bipolar I 
patients. 
 
 
Uric acid (µmol/L)  
Homocysteine 
(µmol/L) 
 
Folate 
(µg/L) 
 
Vitamin 
B12 (ng/L) 
Men 
(n = 85) 
Women 
(n = 45) 
Patients 
 (n = 130) 
311 ± 99 246 ± 97 15.8 ± 8.9 3.3 ± 0.9 356 ± 198 
Illness episode 
Depressive 
 (n = 21) 
228 ± 79 205 ± 128 15.2 ± 6.7 3.4 ± 1.3 481 ± 299a 
Euthymic 
 (n = 73) 
309 ± 110 271 ± 95 16.1 ± 10.1 3.4 ± 0.7 322 ± 165 
Manic 
 (n = 36) 
327 ± 87 217 ± 57 15.5 ± 7.7 3.3 ± 1.2 352 ± 158 
Treatment 
Valproic acid  
 (n = 64) 
328 ± 91 279 ± 109 16.3 ± 10.0 3.5 ± 0.9 361 ± 91 
Lithium 
(n = 12) 
331 ± 79 219 ± 88 17.1 ± 12.7 2.8 ± 0.6 399 ± 79 
Carbamazepine 
(n = 10) 
278 ± 160 207± 61 16.9 ± 9.4 3.2 ± 0.8 240 ± 160* 
AVP and Li 
 (n = 6) 
343 ± 76 288 15.5 ± 2.9 3.0 ± 0.8 518 ± 236* 
Antipsychotics 
 (n = 38) 269 ± 96 218 ± 83 14.2 ± 5.9 3.4 ± 1.5 338 ± 233 
AVP: valproic acid; Li: lithium; *Carb Vs AVP/Li, p = 0.04; aF 2-130 = 5.688, p = 0.004 
Table 11. Variations of uric acid, homocysteine, folate and vitamin B12 concentrations 
according to the illness episode and therapeutic characteristics of bipolar I patients. 
We found a significant association between vitamin B12 values and illness episode (F 2-130 = 
5.688, p = 0.004). Manic patients had lower values of this parameter than depressive 
patients. Moreover, we showed that vitamin B12 was significantly associated with the 
therapeutic characteristics. Indeed, patients taking carbamazepine had significantly lower 
values of this parameter than those taking valproic acid and lithium (p = 0.04) (table 11).  
In patients, there was no significant change in homocysteine, folate and uric acid values in 
relation to illness episodes and the treatment, whereas the lowest values of uric acid were 
seen in depressive patients (both in men and women) compared to manic patients and in 
men taking antipsychotics and women taking carbamazepine compared to the other groups 
(table 11). 
The distribution of BMI according to the illness episode and therapeutic characteristics is 
shown in table 12. 
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Our study failed to show any significant association between the BMI and to the illness 
episode and, therapeutic characteristics. However, we found that obesity was more frequent 
in depressive patients than in those with manic episode (38.1% Vs 27.8%). In addition, 
obesity and overweight were more frequent (72% and 52%; respectively) in patients taking 
valproic acid or lithium (table 12). 
 
BMI (kg/m²) BMI ≥ 30 
n = 43 (%) 
25 ≤ BMI < 30 
n = 40 (%) 
BMI  
< 25 
n = 47 (%) Characteristics 
Illness episode 
Depressive 
 (n = 21) 
8 (38.1) 4 (19.1) 9 (42.8) 
Euthymic 
 (n = 73) 
25 (34.2) 23 (31.5) 25 (34.3) 
Manic 
 (n = 36) 
10 (27.8) 13 (36.1) 13 (36.1) 
Treatment 
Valproic acid  
(n = 64) 
25 (39.1) 17 (26.6) 22 (34.3) 
Lithium 
(n = 12) 
6 (50) 4 (33.3) 2 (16.7) 
Carbamazepine 
 (n = 10) 
2 (20) 5 (50) 3 (30) 
AVP and Li  
(n = 6) 
2 (33.3) 3 (50) 1 (16.7) 
Antipsychotics  
(n = 38) 
8 (21.1) 11 (28.9) 19 (50) 
AVP: valproic acid; Li: lithium 
Table 12. Distribution of BMI according to the illness episode and therapeutic characteristics. 
4. Discussion 
Our study showed that patients had significantly higher levels of triglycerides and Lp(a), 
and significantly lower levels of ApoA1 than control subjects. Furthermore, bipolar I 
disorder was showed to have significant association with hyperLp(a) (47.7% Vs 14.8%, OR = 
4.48, IC 95% = 2.53-7.95; p < 0.001) and hypertriglyceridemia (53.1% Vs 17.7%, OR = 3.71, IC 
95% = 2.13-6.46; p < 0.001).  
In patients, the TG/HDL ratio and Lp(a) were found as the best predictive factors of 
cardiovascular risk in terms of sensibility (0.62, 0.74; respectively) and specificity (0.63, 0.74; 
respectively) at threshold of 1.12 and 168 mg/L, respectively. These results reflect a high 
risk of cardiovascular disease and may explain the high rates of morbidity and mortality in 
this population. Several studies have found mortality rates between 1.5 and 2.5 times higher 
in bipolar patients than the general population. After suicide and accidents, cardiovascular 
and all vascular diseases are the leading causes of death in these patients, with standardized 
mortality ratios ranging from 1.47 to 2.6. (Garcia-Portilla et al., 2009; Sicras et al., 2008). 
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The exact mechanisms increasing the incidence of cardiovascular risk in bipolar patients 
remain to be clarified, but they possibly include industrialisation, stress, lack of exercise, 
dietary lipids (that is, omega-3 fatty acid deficiency), increasing incidence of smoking and 
alcohol consumption and other factors (Ezzaher et al., 2010). These hypotheses will be, in 
part, justified later in this study.  
Several investigators have been hypothesized that abnormalities in fatty acid composition 
may play a role in psychiatric disorders (Horrobin & Bennett, 1999). Maes et al. (1996, 1999) 
reported that patients with major depression had a significantly elevated ratio of 
ecosapentaenoic acid (EPA; 20: 5n-3)/docosahexaenoic acid (DHA; 22: 6n-3), lower level of 
EPA and total n-3 Omega-3 polyunsaturated fatty acids, in both serum cholesteryl esters 
and phospholipids when compared to patients with minor depression and normal controls. 
Similar findings were revealed in terms of fatty acid compositions of the erythrocyte 
membrane (Adams et al., 1996; Edwards et al., 1998; Peet et al., 1998; Chiu et al., 2003). 
Moreover, many prospective and case-control studies have shown a positive association 
between serum triglycerides and coronary artery disease risk and demonstrated the 
importance of fasting triglycerides level as an independent risk factor. A number of clinical 
trials including the Framingham Heart Study have concluded that a low HDL cholesterol 
level predicts the risk for coronary artery disease independently of other risk factors. Each 1 
mg/dL decrease in HDL cholesterol has been shown to increase risk for coronary artery 
disease by 2% in men and 3% in women. The Veterans Affairs High-Density Lipoprotein 
Cholesterol Interventional Trial, investigating the impact of fibrate therapy on 
cardiovascular risk, demonstrated that 6% increase in HDL cholesterol was associated with 
a 22% decrease in coronary events (Kabakci et al., 2008). In addition, Lp(a) has been shown 
to be an independent risk factor for atherosclerosis (Hakim et al., 2008) and has been found 
to exert a broad variety of pro-atherogenic and pro-thrombotic properties (von Eckardstein 
et al., 2001). Elevated plasma Lp(a) has been shown also to be associated with premature 
cardiovascular disease, premature cerebrovascular disease and premature peripheral 
vascular disease (Valentine et al., 1996). 
The underlying mechanism for the altered lipid status in bipolar patients is unclear. A 
possible explanation might be found in the patient’s nutritional status, the decrease in 
physical activity and the medications used (Ezzaher et al., 2010). Additionally, Chung et al. 
(2007) reported that bipolar disorder is associated with perturbations in lipid profile which 
play an important role in the pathophysiology of mood disorders, particularly in bipolar 
disorders. Indeed, cholesterol is one component of circulating lipoprotein particles that, 
besides handling cholesterol, carries micronutrients such as vitamins A and E as well as 
triglycerides and phospholipids. The latter compounds give rise to substrates such as fatty 
acids and choline, which are used in both the structural lipids of neuronal membranes and 
intercellular communication. Therefore, higher levels of one or more compounds of 
lipoprotein particles circulating in the bloodstream may produce subtle but measurable 
enhancements of mental processes by influencing the supply of fat-soluble micronutrients, 
specific fatty acids, or structural lipids (Ezzaher et al., 2010). 
Our study failed to found any significant association between lipid profile parameters and 
illness episode, while euthymic patients were found to have the highest levels of Lp(a). 
Additionally, depressive patients had the highest levels of ApoB/Apo A1 ratio. However, 
some authors (Sagud et al., 2009) showed that serum cholesterol and LDL values were 
significantly lower in manic patients and others (Chung et al., 2007) showed that there 
was no difference in mean serum level of cholesterol or triglycerides among patients with 
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manic, mixed, or depressive episode. These differences could be due to ethnicity and 
eating habits. 
About therapeutic characteristics, any significant association was shown between lipid 
profile parameters and treatment, while, women taking lithium had the lowest c-HDL 
values and patients taking carbamazepine had the highest values of Lp(a). The 
mechanism(s) by which these drugs exert weight gain are not well known, but are 
presumed to involve increased energy intake (e.g., overeating), decreased energy 
expenditure (e.g., reduced resting metabolic rate, reduced physical activity, or reduced diet-
induced thermogenesis), or a combination of the two (Malhotra & McElroy, 2002). 
Additionally, we found that the prevalence of metabolic syndrome was 26.1% among 
patients, 24.7% in men and 28.8% in women. These prevalences were definitely higher than 
those reported in the Tunisian general population (13% in men and 18% in women) using a 
previous criteria (Bouguerra et al., 2006).  
Compared with other studies, the prevalence of metabolic syndrome in our patients is 
included between those in Spanish patients (22.4%), Italian patients (25.3%) and US patients 
(30%) (Garcia-Portilla et al., 2008; Salvi et al., 2008; Fagiolini et al., 2005). The increasing 
prevalence of metabolic syndrome is important because it confers greater cardiovascular 
morbidity and mortality. Prospective observational studies have demonstrated an 
association between metabolic syndrome and development of type II diabetes (Hanson et 
al., 2002; Resnick et al., 2003; Klein et al., 2002; Sattar et al., 2003), cardiovascular disease 
(Lakka et al., 2002; Kip et al., 2004), and stroke (Kurl et al.,2006). 
Our study showed that the highest prevalence of metabolic syndrome was obtained by the 
association between obesity, low c-HDL and hypertriglyceridemia. Moreover, the most 
individual components of this syndrome, in the total sample of patients, was low c-HDL 
(59.2%), hypertriglyceridemia (53.1%) and obesity (BMI ≥ 28.5 kg/m²) (33.8%), confirming in 
part the higher risk of dyslipidemia and obesity in bipolar I patients and in other hand the 
higher risk of cardiovascular disease in this population.  
We found no significant difference in the prevalence of metabolic syndrome among gender 
and age. This is in line with results reported by Yumru et al., (2007).  
We noted that there was no significant change in the prevalence of metabolic syndrome in 
relation to illness episode; however, manic patients had the highest prevalence. This may 
explain the high risk of cardiovascular disease in manic patients compared with depressive 
one (Murray et al., 2009). Additionally, Angst et al. (2002) showed that individuals with 
bipolar I disorder are at greater risk for cardiovascular mortality than individuals with 
bipolar II disorder. However, the difference in cardiovascular mortality between the two 
bipolar subtypes reflects the manic symptom burden, which predicts cardiovascular 
mortality independently of diagnosis and cardiovascular risk factors at intake. The results 
suggest that mania, either directly (through factors intrinsic to illness) or indirectly (through 
other mediators or associated variables), may itself influence cardiovascular disease. 
Our study failed to show any significant association between metabolic syndrome and 
treatment. However, we noted that patients treated with lithium had the highest prevalence 
of metabolic syndrome. The increased risk to develop metabolic syndrome during treatment 
with lithium is in part related to its propensity to induce weight gain. According to Casey, 
lithium has been shown to stimulate appetite and increase calorie intake through different 
mechanisms. 
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HOMA-IR is significantly higher in patients with metabolic syndrome than others. This 
increase in HOMA-IR values reflects an insulin resistance and is associated with two to 
three fold increases in cardiovascular disease independent of classical risk factors (Toalson 
et al., 2004). In addition, uric acid levels were significantly higher in patients with metabolic 
syndrome. According to Vuorinen-Markkola et al. (1994), hyperuricemia forms another 
consistent feature of the metabolic syndrome what led to the suggestion of uric acid being a 
new component of the syndrome. 
In addition, Chien et al., (2008) reported that metabolic syndrome induces high oxidative 
stress and the accompanying hyperuricemia worsens this stress. Furthermore, uric acid 
stimulates vascular smooth muscle proliferation, induces endothelial dysfunction, decreases 
endothelial nitric oxid production, and consequently, makes peripheral tissue resistant to 
insulin effects and results in endothelial dysfunction (Chien et al., 2008). High levels of uric 
acid are associated with increased renal glomerular pressure and sodium reabsorption, 
enhanced by high insulin concentrations (Alkerwi et al., 2009). In addition, hyperuricemia 
was associated with insulin resistance markers, including triglycerides, microalbuminuria 
and impaired glucose tolerance. These disturbances contribute to increase cardiovascular 
risk (Chien et al., 2008). This insulin- resistance causes steatosis, which is associated with 
hyper secretion of hepatic enzymes (Fromenty et al., 2004). 
In men, uric acid was significantly higher in patients than controls. Additionally, the risk 
of hyperuricemia in bipolar I patients was approximately multiplied by 1.5 (10.8% Vs 
4.4%, OR = 1.58, IC 95% = 0.49-5.08; p = 0.439). Many, but not all, epidemiological studies 
have suggested that high plasma uric acid is a risk factor for cardiovascular diseases. This 
raised level of plasma uric acid, parallel to an increased risk of cardiovascular diseases, 
could be either primary or secondary to the underlying causes of the cardiovascular 
diseases. However, the specific role of plasma uric acid in this constellation remains 
uncertain, although it may be involved in the platelet adhesiveness, aggregation, or 
inflammation and it may be implicated in the genesis of hypertension. In contrast, there is 
some evidence that the increase of plasma uric acid is protective against the 
cardiovascular diseases, since uric acid acts as an endogenous antioxidant, and the higher 
plasma uric acid levels found in cardiovascular diseases patients suggest that any 
protective antioxidant effect of uric acid is hidden by other negative effects in these 
pathogeneses (Haj mouhamed et al., 2010). 
Additionally, Torres et al. (2007), reported that hyperuricemia which implicated in the 
oxidative stress plays an important role in the pathophysiology of bipolar disorders. The 
idea that the purinergic system might be involved in bipolar disorder dates back to 
Kraepelin, who was the first to describe an association between manic symptoms, uric acid 
excretion, hyperuricemia, and gout. In fact, the purinergic system modulates sleep, motor 
activity, cognition, attention, behavior, and mood. Even in the absence of a psychiatric 
diagnosis, individuals with higher uric acid levels are more likely to show higher drive, 
disinhibition, hyperthymia, or irritable temperament (Lorenzi et al., 2010). Similarly, 
diseases characterized by purinergic turnover dysfunction and uric acid overproduction 
(e.g., Lesch–Nyhan syndrome) are associated with impulsive/aggressive behavior, 
disinhibition, and increased sexual drive (Salvadore et al., 2010).  
Among clinical and therapeutic characteristics, we found that there was no significant 
change in uric acid values in relation to illness episodes and the treatment. This finding is 
not in agreement with the previous studies that reported that plasma uric acid levels were 
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higher only during the manic phase of bipolar disorder but not during the depressive or 
euthymic phases (De Berardis et al., 2008). Additionally, lithium was found to low uric acid 
plasma levels and to have uricosuric effects in mania. Carbamazepine and phenytoin 
similarly decreased uric acid levels; in contrast, valproate appeared to have the opposite 
effect. However, it is important to note that the effect of these drugs on uric acid levels in 
relationship to clinical improvement in patients with bipolar disorder has not been 
systematically evaluated (Salvadore et al., 2010). 
Compared with controls, patients had significantly higher levels of homocysteine and 
significantly lower levels of folatemia. Additionally, significant associations were showed 
between bipolar I disorder and hyperhomocysteinemia (39.2% Vs 18%, OR = 1.95, IC 95% = 
1.04-3.69; p = 0.038) and hypofolatemia (66.2% Vs 36.2%, OR = 3.69, IC 95% = 2.20-6.19; p < 
0.001). Homocysteine is an intermediary metabolite of the essential amino acid methionine. 
Folate and vitamin B12 are required for remethylation of homocysteine to methionine 
(Hankey & Eikelboom, 1999).  
According to Reynolds (2006), hyperhomocysteinaemia has long been identified as a risk 
factor for vascular disease and the lowering of homocysteine concentrations by the 
treatment with folic acid, or possibly vitamin B12 and vitamin B6 which might reduce the 
risk of both cardiovascular and cerebrovascular diseases. Moreover, the association between 
increased circulating homocysteine concentrations and premature vascular thrombotic 
events in individuals with hereditary homocystinuria is well established. This process may 
include platelet activation, smooth muscle cell proliferation, and enhanced leukocyte 
binding to the endothelium. In recent years, a relationship between milder degrees of 
hyperhomocysteinaemia and vascular disease has emerged, and this has been the subject of 
intense research. Hyperhomocysteinemia can be caused by a wide range of disorders, the 
most important of which are genetic defects of the enzymes involved in homocysteine 
metabolism and/or deficiencies of their co-factors: folate (former vitamin B9), vitamin B12 
and vitamin B6 (Haj mouhamed et al., 2011).  
Our study showed a significant association between bipolar I disorder and 
hyperhomocysteinemia. The exact mechanisms underlying the hyperhomocysteinemia in 
this disease are not completely understood and controversed among studies. Several 
hypotheses have been postulated including nutritional folate and vitamin B deficiency, 
and/or reduced glomerular filtration rate in bipolar patients (Vuksan-Ćusa et al., 2011). En 
effect, we found a significant association between this disease and hypofolatemia. 
Furthermore, some authors (Atmaca et al., 2005) showed that at a high concentration, 
homocysteine is considered to be a neurotoxic substance, causing activation of NMDA (N-
methyl D-aspartate) receptors and leading to excitotoxicity. By impairing the neural 
plasticity and promoting neuronal degeneration, homocysteine could contribute to the 
pathogenesis of neurodegenerative and psychiatric disorders (Ipcioglu et al., 2008). 
Additionally, homocysteine is a methyl donor when activated to S-adenosylmethionine. So 
aberrant DNA methylation due to hyperhomocysteinemia also may be involved in the 
pathogenesis of bipolar disorder as well as schizophrenia (Mill et al., 2008). 
In the other hand, folate appears to influence the synthesis rate of tetrahydrobiopterin, a 
cofactor in the hydroxylation of phenylalanine and tryptophan, rate-limiting steps in the 
biosynthesis of dopamine, norepinephrine, and serotonin, neurotransmitters postulated to 
play a role in the monoamine hypothesis of affective disorders. In addition, methyl 
tetrahydrofolate has been shown to bind to presynaptic glutamate receptors, where it may 
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potentially modulate the release of other neurotransmitters, including the monoamines 
(Atmaca et al., 2005). 
Moreover, some studies showed that lower folatemia in patients with psychiatric disorders 
can be due to their nutritional status (Reif et al., 2005). Indeed, poor appetite as a symptom 
of bipolar disorder could lead to decreased intake of B vitamins which could then lead to 
elevated homocysteine concentrations (Tolmunen et al., 2004). 
We found a significant association between vitamin B12 values and illness episode. Manic 
patients had lower values of this parameter than depressive patients. This can be explained 
by the eating habits of bipolar patients. Indeed, Parikh et al. (2000) found that manic episode 
is often associated with weight loss. 
About therapeutic characteristics, we showed that only vitamin B12 was significantly 
associated with the medication use. Indeed, patients taking carbamazepine had significantly 
lower values of this parameter than those taking valproic acid and lithium. These findings 
are not in agreement with others studies. In fact, Derkes and Westphal (2005) showed that 
carbamazepine can cause elevated homocysteine concentrations. Although, according to 
Ozbek et al (2008), homocysteine, folate and vitamin B12 were not related to drug usage. 
Additionally, Osher et al (2008) reported that there were no significant differences in 
homocysteine levels between patients receiving versus not receiving lithium, neuroleptic or 
valproate. However, Sener et al. (2006) suggested that carbamazepine, as enzyme inducer, 
can directly modulate the activity of different liver enzymes. Liver enzyme induction may 
cause depletion of the cofactor involved, folic acid, pyridoxal 5’-phosphate and vitamin B12, 
leading to the alterations in homocysteine status.  
Our study showed that bipolar I patients are so much more likely to be smokers than 
controls (52.3% Vs 39.4%, OR = 1.68, IC 95% = 1.06-2.66; p = 0.025). An association between 
smoking and bipolar I disorder has been established and prevalence rates for lifetime and 
current smoking have been shown to be as high as 82.5% and 68.8% respectively (Lasser et 
al., 2000). The possible explanations for the high rates of smoking include an increased 
genetic vulnerability, a greater susceptibility to addiction because of a greater subjective 
experience of reward or pleasure, or that tobacco helps relieve some of the symptoms 
related to a behavioural disorder. For example, cigarette smoking may be an attempt to self-
medicate symptoms of depression, anxiety, boredom or loneliness. Other possible 
explanations for continuing to smoke include increased withdrawal symptoms and reduced 
side effects from psychiatric medication (Williams & Ziedonis, 2004). Additionally, it has 
been reported that nicotine stimulates the brain to release dopamine, which is associated 
with pleasurable feelings, and smokers quickly develop regular smoking patterns. 
Eventually, smokers need increasing levels of nicotine to feel ‘normal’. In the other hand, 
cigarette smoking is known to contribute to many diseases, including cancer, chronic 
obstructive pulmonary disease, stroke, cardiovascular diseases, and peptic ulcers. 
Investigators have attempted to elucidate the mechanisms of the pathogenesis associated 
with cigarette smoking, but the conclusions were not consistent. A basic hypothesis is that 
free radicals cause oxidative damage to macromolecules such as lipids, proteins, and DNA. 
Therefore, these radicals play an important role in the pathogenesis of these diseases (Haj 
mouhamed et al., 2010). 
In this study, the prevalence of obesity is higher in patients with bipolar I disorder than in 
controls. Moreover, the risk of obesity in these patients is approximately multiplied by nine 
(33.1% Vs 8%, OR = 8.69, IC 95% = 3.61-20.87; p < 0.001).  
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In bipolar I patients, the prevalences of obesity and overweight were respectively 33.1 % and 
30.7 %. These findings were similar to those reported by Elmslie et al (2000) and Fagiolini et 
al (2002) (36 % and 32 %). However, higher values were reported by McElroy et al (2004) (44 
% and 20 %).  
For this population, we found that the prevalence of obesity greatly exceeded that found in 
controls (12.3%) and in the general population (20%) (Haddad et al., 2006). Obesity in 
patients with bipolar I disorder thus constitutes a major public health problem and suggests 
that the development and testing of specific interventions that target the obesity epidemic in 
this particular population are urgently needed. Bipolar disorder and obesity both have 
tremendous impact on the physical and mental well-being of affected individuals. 
Therefore, both illnesses should be treated with a coordinated intensive and multifaceted 
treatment (Fagiolini et al., 2003). 
Moreover, the risk of obesity in these patients is approximately multiplied by nine (33.1% Vs 
8%, OR = 8.69, IC 95% = 3.61-20.87; p < 0.001). This could be one of the missing factors in 
understanding the relationship between psychiatric disorders and increased cardiovascular 
risk. In fact, some studies have reported that psychiatric disorders, particularly bipolar 
disorder, are significantly associated with adverse cardiovascular events and coronary heart 
disease (Garcia-Portilla et al., 2009). The mechanisms through which obesity leads to 
coronary heart disease remain hotly debated, but the accumulation, particularly, of visceral 
fat is widely favoured as the primary mechanism, leading, through the release of fatty acids 
and other mediators, to insulin resistance, dyslipidaemia, and a pro-inflammatory state. 
However, obesity in general, and central obesity in particular (ie. excessive visceral intra-
abdominal fat) have been under-recognised as risk factors for coronary heart disease in the 
population, where most attention has been placed on smoking and cholesterol (Pinkney, 
2001).  
According to Raji et al (2009), the cardiovascular afflictions including obesity, diabetes, 
hypertension and stroke increase the risk for cognitive decline and dementia, but it is 
unknown whether these factors, specifically obesity and type 2 diabetes mellitus, are 
associated with specific patterns of brain atrophy. Obesity and type 2 diabetes mellitus may 
amplify the risk for dementia by worsening cerebral atrophy even in cognitively intact 
individuals, raising their vulnerability to future Alzheimer’s disease neuropathology. 
The same authors, mostly in subjects younger than 65 years, suggest also that increased 
body tissue fat content (adiposity) is correlated with atrophy in the temporal cortex, frontal 
lobes, putamen, caudate, precuneus, thalamus, and white matter. It is unknown, but of great 
interest, whether high tissue fat content, as measured by BMI, is associated with differences 
in brain structure in cognitively normal elderly (Raji et al., 2009). 
Additionally, some studies showed that obesity has psychosocial consequences, including 
discrimination and stigmatization, which may contribute to the severity of bipolar disorder 
by negatively impacting patients’ general physical health and functioning, quality of life, 
self-esteem, and psychological well-being. Obese patients have an increased risk of sleep 
apnea, which causes sleep disruptions and may lead to mood destabilization in patients 
with bipolar disorder. Obesity may also impact effectiveness of pharmacotherapies by 
altering the distribution and elimination of medications. Truncal obesity, which is most 
common, increases the risk of type 2 diabetes mellitus, dyslipidemia, hypertension, stroke, 
ischemic heart disease, and early death (Cheymol, 2000; Fagiolini et al., 2003; Plante & 
Winkelman, 2008).  
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In addition, obesity was more frequent in depressive patients than in those with manic 
episode (38.1% Vs 27.8%). Previous studies reported that patients who had depressive 
symptomatology were more likely to have excessive caloric and cholesterol intake, to smoke 
and to be inactive than non-depressed subjects. Another explanation might involve 
biological mechanisms: it is ascertained that hypothalamic–pituitary- adrenal (HPA) axis 
dysregulation and high cortisol blood levels lead to increased visceral fat. HPA axis 
dysregulation has been a common finding in both unipolar and bipolar disorders; recently, 
some studies reported that increased cortisol blood levels correlated to the amount of intra-
abdominal fat in major depression (Maina et al., 2008). 
About therapeutic characteristics, we found that obesity and overweight were more 
frequent (72% and 52%; respectively) in patients taking valproic acid or lithium. These 
findings are in line with those reported by De Hert et al. (2011). Moreover, Casey et al. 
(2005) reported that lithium have been shown to stimulate appetite through different 
mechanisms. The “carbohydrate craving” that is thought to be one of the mechanisms of 
increased calorie intake in people taking lithium is well known. In addition, it is believed 
that valproate also stimulates weight gain through a variety of mechanisms, especially the 
development of insulin resistance and diabetes mellitus type 2. In this line, our study found 
that this type of diabetes is frequent in patients (16.2%). Additionally, the risk of diabetes is 
multiplied by 1.5 in patients (16.2% Vs 9.7%, OR = 1.60, IC 95% = 0.62-4.12; p = 0.325).  
Previous studies suggested that patients with both bipolar disorder and comorbid diabetes 
have more lifetime psychiatric hospitalizations than patients with bipolar patients without 
diabetes. The association between these two disorders underscores the importance of 
screening for diabetes in patients with bipolar illness, particularly because early detection 
and initiation of treatment to control glycemia may prevent diabetes-related complications. 
Moreover, other studies have demonstrated cerebrovascular lesions involving small 
intraparenchymal cerebral vessels and focal infarctions in patients with diabetes. These 
lesions predominantly occur in areas providing blood supply to the base of the pons, 
thalamus, and basal ganglia. Diabetes has been implicated as a risk factor for subcortical 
white-matter lesions observed on magnetic resonance imaging (MRI) scans; similar MRI 
findings have been noted in patients with bipolar disorder. Cerebral microvascular disease 
may lead to greater frequency of manic episodes, another reason to minimize diabetes-
related complications in patients with comorbid bipolar disorder (Cassidy et al., 1999; 
Holman et al., 2008). 
Alcoholic beverage was not significantly associated with this illness but we showed that it 
was more frequent in patients than controls (13.1% Vs 6.9%, OR = 2.04, IC 95% = 0.94-4.44; p 
= 0.067). It has been well documented that bipolar disorder and alcoholism commonly co-
occur. In fact, the lifetime prevalence of alcohol abuse and drug abuse in people with bipolar 
disorder are known to be three to nine times more frequent that of the general population 
(Merikangas et al., 2007; Regier et al., 1990; ten Have et al., 2002).  
Additionally, some studies showed that the feelings of depression and anxiety associated 
with bipolar can be a factor that leads to alcoholism. People with bipolar disorder may use 
alcohol or other drugs to self medicate these feelings, especially in instances where the 
person has not been diagnosed. However, alcohol makes the symptoms of bipolar disorder 
worse. Anyone who shows symptoms of bipolar disorder should seek the advice of medical 
professionals (Le Strat, 2010). 
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Some studies have shown that alcohol directly contributes to heart disease and stroke. 
Heavy drinking raises levels of triglycerides circulating in the bloodstream leading to 
diabetes and blocked or narrowed arteries that carry blood to the heart. If coronary arteries 
are clogged with fats, blood cannot flow freely, resulting in heart disease or stroke. 
Additionally, alcohol directly contributes to heart failure by damaging the heart muscle and 
arteries. Cardiomyopathy, or an enlargement of the heart muscle, results from long-term 
alcohol use. An enlarged heart no longer works efficiently and fails to provide enough 
oxygenated blood to other organs of the body. Furthermore, alcohol is associated with 
cardiac arrhythmia (irregular heartbeat), sudden cardiac death, stroke and atrial fibrillation 
(Pearson, 1996).  
In our patients, hypertension was not associated with bipolar disorder (5.4% Vs 16%, OR = 
0.43, IC 95% = 0.14-1.29; p = 0.136). De Heart et al. (2010) explained the decrease of 
hypertension frequency in individuals with a mental illness by changes in lifestyle of 
patients such as reducing salt intake. 
Several methodological limitations should be considered when interpreting these findings. 
First, larger sample sizes of groups would be beneficial. Second, our work is a cross-
sectional study that does not permit to follow up biological parameters. Third the sample of 
bipolar patients may not be representative of more heterogeneous populations. Finally, the 
diagnosis of controls was made by psychiatrists but without formal use of structured 
instruments to exclude psychiatric disorders in controls. 
5. Conclusion 
Our results demonstrate that Tunisian bipolar I patients are exposed to higher 
cardiovascular risk. In fact, they had perturbations in lipid profile: significantly higher 
values of triglycerides and Lp(a), and significantly lower values of ApoA1, significantly 
hyperhomocysteinemia and hyperuricemia (in men), significantly hypofolatemia and high 
prevalence of metabolic syndrome. Obesity, hyperLp(a), hypertriglyceridemia, 
hypofolatemia, hyperhomocysteinemia and cigarette smoking were the main cardiovascular 
risk factors associated with bipolar I disorder. Indeed, the risk of obesity was increased 
approximately for nine once, hyperLp(a), hypertriglyceridemia and hypofolatemia 
approximately for four once and the other factors approximately for tow once. The 
TG/HDL ratio and Lp(a) were found as the best predictive factors of cardiovascular risk in 
terms of sensibility and specificity at threshold of 1.12 and 168 mg/L, respectively.  
Our findings noted a significant association between vitamin B12 values and illness episode. 
Manic patients had lower values of this parameter than depressive patients. Moreover, we 
showed that vitamin B12 was significantly associated with the therapeutic characteristics. 
Indeed, patients taking carbamazepine had significantly lower values of this parameter than 
those taking valproic acid and lithium. Additionally, there was no significant change in 
homocysteine, folate, uric acid values and metabolic syndrome in relation to illness episode 
and the treatment, whereas the patients with metabolic syndrome had significant higher 
levels of HOMA-IR and uric acid than metabolic syndrome free.  
Therefore, bipolar I patients require specific care, particularly for lipid profile, vitamin 
status and weight; the effectiveness of this care will be evaluated during follow-up period 
Clinicians should track the effects of treatment on physical and the biological parameters, 
and should facilitate access to appropriate medical care. 
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